Journal
FARMACIA
Volume 68, Issue 3, Pages 377-383Publisher
SOC STIINTE FARMACEUTICE ROMANIA
DOI: 10.31925/farmacia.2020.3.1
Keywords
COVID-19; SARS-CoV-2; diabetes; of renin-angiotensin-aldosterone system; RAAS; ACEi; ARBs
Categories
Funding
- Carol Davila University of Medicine and Pharmacy - Ministry of Research and Innovation within PNCDI III, Program 1 - Development of the National RD system, Subprogram 1.2 - Institutional Performance - RDI excellence funding projects [23PFE/17.10.2018]
Ask authors/readers for more resources
In the context of the COVID-19 continuous spreading, this paper focuses on the increased risk of diabetic patients regarding the metabolic control and the uncertainties related to SARS-CoV-2 infection. Chronic hyperglycaemia negatively affects the immune system, which triggers an increase of morbidity and mortality for viral infections. A key aspect of COVID-19 resides in the involvement of renin-angiotensin-aldosterone (RAAS) system that causes a cascade of reactions mediated by vasoactive peptides with implications in vasoconstriction, vascular permeability, oxidative stress remodelling and tissue injuries. Activation of RAAS at pulmonary level, is responsible for the local damage. Many questions regarding the treatment with ACE inhibitors and angiotensin receptor blockers were raised considering the correlation between RAAS and viral infection in diabetic patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available